213 related articles for article (PubMed ID: 33431672)
1. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
[TBL] [Abstract][Full Text] [Related]
2. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
3. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
4. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
[TBL] [Abstract][Full Text] [Related]
5. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
7. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
8. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ
Brain; 2008 May; 131(Pt 5):1294-302. PubMed ID: 18362097
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease.
Baik K; Cha J; Ham JH; Baek GM; Sunwoo MK; Hong JY; Shin NY; Kim JS; Lee JM; Lee SK; Sohn YH; Lee PH
Hum Brain Mapp; 2014 Nov; 35(11):5431-41. PubMed ID: 24938993
[TBL] [Abstract][Full Text] [Related]
10. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
11. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
12. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; Rehncrona S; Widner H; Lindvall O
Nat Neurosci; 1999 Dec; 2(12):1137-40. PubMed ID: 10570493
[TBL] [Abstract][Full Text] [Related]
13. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
16. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
[TBL] [Abstract][Full Text] [Related]
17. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
18. [
Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
[TBL] [Abstract][Full Text] [Related]
20. Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
Sacheli MA; Neva JL; Lakhani B; Murray DK; Vafai N; Shahinfard E; English C; McCormick S; Dinelle K; Neilson N; McKenzie J; Schulzer M; McKenzie DC; Appel-Cresswell S; McKeown MJ; Boyd LA; Sossi V; Stoessl AJ
Mov Disord; 2019 Dec; 34(12):1891-1900. PubMed ID: 31584222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
